SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual fireside chat at 12:00 p.m. ET / 9:00 a.m. PT on Wednesday, December 6, 2023.
A live webcast of the fireside chat will be available here and in the Investors & Media Section of Sagimet’s website at www.sagimet.com, with an archived replay available following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of NASH, for which there are no treatments currently approved in the United States or Europe. Denifanstat is currently being tested in FASCINATE-2, a Phase 2b clinical trial in NASH with liver biopsy as the primary endpoint. For additional information about Sagimet, please visit www.sagimet.com.
Source: Sagimet Biosciences Inc.